Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Pharmaceutical goods appear to be exempt from higher-rate tariffs introduced by President Trump in his 'Liberation Day' ...

FTSE 100 p harma giants GSK and Astrazeneca may have escaped the worst of US President Donald Trump’s tariffs, according to a ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

Pharma stocks rise as Trump exempts pharmaceuticals from reciprocal tariffs. Indian, UK, and Japanese drugmakers gain.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

We recently published a list of 8 Most Undervalued Healthcare Stocks to Buy According to Analysts. In this article, we are ...

Shares of surprise tariff avoiders like pharmaceuticals and drinks firms and rate-sensitive stocks such as real estate were ...

Learn more about whether Corcept Therapeutics Incorporated or GSK plc is a better investment based on AAII's A+ Investor ...

The PA news agency looks at which sectors will be most affected by the plans and what it means for businesses and households.

Topline results from the groundbreaking Salford Lung Study are encouraging for GSK's new respiratory drug - but the 'real world' story isn't quite so simple. GlaxoSmithKline (GSK) has announced ...

GlaxoSmithKline (GSK) continues to be the subject of takeover speculation, with Roche and Johnson & Johnson (J&J) now rumoured to be interested in bidding for the UK firm. There does not seem to ...